Latent membrane protein 1-derived peptide–major histocompatibility complex (LMP1-pMHC)

Latent membrane protein 1 (LMP1)-derived peptide–major histocompatibility complex (MHC) refers to the presentation of specific Epstein-Barr virus (EBV) antigenic fragments on the surface of infected or malignant cells (PMID: 25407630). LMP1 is the primary oncogene of EBV and is essential for B-cell transformation and the survival of EBV-associated tumor cells (PMID: 15155838). Since LMP1 is a transmembrane protein with minimal extracellular exposure, its presentation as peptide-MHC complexes (pMHC) is the primary way the immune system identifies infected cells. The most well-characterized epitope is the YLQQNWWTL peptide presented by HLA-A*02:01 (PMID: 31515463). These complexes are considered high-value therapeutic targets because they are tumor-specific and absent from healthy EBV-negative tissues. Current drug development focuses on T-cell receptor (TCR)-like antibodies and TCR-engineered T cells that can recognize these pMHCs with high affinity. Targeting these complexes allows for the treatment of EBV-associated malignancies such as nasopharyngeal carcinoma and certain lymphomas. However, challenges include the low density of these complexes on the cell surface and the requirement for patients to possess specific HLA alleles.

Other names

LMP1-HLA-A*02:01 complexEBV LMP1 peptide-MHC complexYLQQNWWTL-HLA-A*02:01 complexLMP1-MHC class I complex

Therapeutic agents (TCRs or TCR-like antibodies) bind specifically to the LMP1 peptide-MHC complex on the cell surface, initiating a cytotoxic immune response that leads to the apoptosis or lysis of the EBV-infected or malignant cell.